Categories
Ailmemts & Remedies

Kidney Cancer

Definition:
Kidney cancer is usually defined as a cancer that originates in the kidney.

CLICK & SEE THE PICTURES

The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
The distinction between these two types (RCC and UCC) is important because their prognosis, staging, and management, i.e. treatment (e.g. surgery, chemotherapy etc.), are different.

Renal cell carcinoma (RCC) is the most common type in adults, responsible for approximately 80 per cent of cases.

Types:
In addition to renal cell carcinoma and renal pelvis carcinoma, other, less common types of kidney cancer include:

*Squamous cell carcinoma
*Juxtaglomerular cell tumor (reninoma)
*Angiomyolipoma
*Renal oncocytoma
*Bellini duct carcinoma
*Clear-cell sarcoma of the kidney
*Mesoblastic nephroma
*Wilms’ tumor, usually is reported in children under the age of 5.
*Mixed epithelial stromal tumor

Rarely, some other types of cancer and potentially cancerous tumors that more usually originate elsewhere can originate in the kidneys. These include:

*Clear cell adenocarcinoma
*Transitional cell carcinoma
*Inverted papilloma
*Renal lymphoma
*Teratoma
*Carcinosarcoma
*Carcinoid tumor of the renal pelvis

Cancer in the kidney may also be secondary, the result of metastasis from a primary cancer elsewhere in the body.

Around 208,500 new cases of kidney cancer are diagnosed in the world each year, accounting for just under 2% of all cancers. The highest rates are recorded in Northern America and the lowest rates in Asian and African regions.

In the United States in 2008, these two types together are estimated to cause 54,390 new cases and 13,010 deaths.

2005. The most recent estimates of incidence of kidney cancer suggest that there are 63,300 new cases annually in the EU25. In Europe, kidney cancer accounts for nearly 3% of all cancer cases.

In the UK kidney cancer is the eighth most common cancer in men, with 4,622 new cases diagnosed in 2005. This compares to 2,758 new cases of kidney cancer in women, giving a male:female ratio of 1.5:1. In women it is the fourteenth most common cancer. Male kidney cancer incidence rates increased by more than 85% from 7.1 per 100,000 in 1975 to 13.4 per 100,000 in 2005. In women the rates have more than doubled over the same period from 3.2 to 6.6 per 100,000. Most of the increase has occurred in older men and women, with rates more than doubling between 1975 and 2005 for men in their 70s and early 80 and women aged 65 and over. The incidence of the disease in Britain has an aspect ratio of 50.6% of the final exitus( quote by Welsh Cancer Intelligence, 2005 ).

The incidence of kidney cancer is increasing also in the United States, and this increase is thought to be real, at least in part, not due only to changes in diagnostic practices.

Some types of kidney cancer have a known hereditary or familial risk, and to date five hereditary syndromes have been associated with renal cell carcinoma

Symptoms:
Many people with kidney cancer have no symptoms at first, especially when the cancer is small. The affected kidney will become larger and in time, the tumour may grow through the wall of the kidney and invade nearby tissues and organs, such as the muscles around the spine, liver and nearby large blood vessels.

As the cancer develops, the following may occur:

•Blood in the urine, which is usually painless and may ‘come and go’ as the tumour bleeds (the first symptom in 60 per cent of cases)
•Pain in the back or side
•Swelling in the abdomen
•High blood pressure
•Feeling generally unwell or tired
•Loss of appetite
•Polycythaemia (too much blood in body) or anaemia (too little)
•Varicocele (tangled network of veins in the scrotum)
•Hip fracture, owing to spread of the cancer to bone
•Excessive hair growth in females
•Feeling thirsty
•Night sweats
•Severe weight loss

Causes:
Kidney cancer develops most often in people over 40, but no one knows the exact causes of this disease. Doctors can seldom explain why one person develops kidney cancer and another does not. However, it is clear that kidney cancer is not contagious. No one can “catch” the disease from another person.

Research has shown that people with certain risk factors are more likely than others to develop kidney cancer. A risk factor is anything that increases a person’s chance of developing a disease.

Studies have found the following risk factors for kidney cancer:

•Smoking: Cigarette smoking is a major risk factor. Cigarette smokers are twice as likely as nonsmokers to develop kidney cancer. Cigar smoking also may increase the risk of this disease.
•Obesity: People who are obese have an increased risk of kidney cancer.
•High blood pressure: High blood pressure increases the risk of kidney cancer.
•Long-term dialysis: Dialysis is a treatment for people whose kidneys do not work well. It removes wastes from the blood. Being on dialysis for many years is a risk factor for kidney cancer.
•Von Hippel-Lindau (VHL) syndrome: VHL is a rare disease that runs in some families. It is caused by changes in the VHL gene. An abnormal VHL gene increases the risk of kidney cancer. It also can cause cysts or tumors in the eyes, brain, and other parts of the body. Family members of those with this syndrome can have a test to check for the abnormal VHL gene. For people with the abnormal VHL gene, doctors may suggest ways to improve the detection of kidney cancer and other diseases before symptoms develop.
•Occupation: Some people have a higher risk of getting kidney cancer because they come in contact with certain chemicals or substances in their workplace. Coke oven workers in the iron and steel industry are at risk. Workers exposed to asbestos or cadmium also may be at risk.

Diagnosis:-

If a patient has symptoms that suggest kidney cancer, the doctor may perform one or more of the following procedures:

•Physical exam: The doctor checks general signs of health and tests for fever and high blood pressure. The doctor also feels the abdomen and side for tumors.
•Urine tests: Urine is checked for blood and other signs of disease.
•Blood tests: The lab checks the blood to see how well the kidneys are working. The lab may check the level of several substances, such as creatinine. A high level of creatinine may mean the kidneys are not doing their job.
•Intravenous pyelogram (IVP): The doctor injects dye into a vein in the arm. The dye travels through the body and collects in the kidneys. The dye makes them show up on x-rays. A series of x-rays then tracks the dye as it moves through the kidneys to the ureters and bladder. The x-rays can show a kidney tumor or other problems.
•CT scan (CAT scan): An x-ray machine linked to a computer takes a series of detailed pictures of the kidneys. The patient may receive an injection of dye so the kidneys show up clearly in the pictures. A CT scan can show a kidney tumor.
•Ultrasound test: The ultrasound device uses sound waves that people cannot hear. The waves bounce off the kidneys, and a computer uses the echoes to create a picture called a sonogram. A solid tumor or cyst shows up on a sonogram.
•Biopsy: In some cases, the doctor may do a biopsy. A biopsy is the removal of tissue to look for cancer cells. The doctor inserts a thin needle through the skin into the kidney to remove a small amount of tissue. The doctor may use ultrasound or x-rays to guide the needle. A pathologist uses a microscope to look for cancer cells in the tissue.
•Surgery: In most cases, based on the results of the CT scan, ultrasound, and x-rays, the doctor has enough information to recommend surgery to remove part or all of the kidney. A pathologist makes the final diagnosis by examining the tissue under a microscope.

Treatment:
Treatment options which may be considered include:

•Surgery to remove all (or part) of the affected kidney. This is the most common treatment and can be done as a keyhole operation in some cases. If the cancer is at an early stage and hasn’t spread, surgery alone may be enough. If the cancer has spread, surgery to remove the affected kidney may still be advised, often in addition to further surgery to remove a secondary kidney tumour (one which has spread to another part of the body).
•Radiotherapy may be advised to kill any cancerous cells left behind following an operation.
•Arterial embolisation may be used instead of surgery, where the artery to the kidney tumour is blocked. The blood supply to the tumour is then cut off, and the tumour dies.
•Medications such as sunitinib, temsirolimus, bevacizumab, interferon-alpha have improved the outlook for kidney cancer patients. Speak to your specialist about what may be best for you.
Chemotherapy doesn’t work as well as it does for other types of cancer. The type of treatment depends on the type and how large the cancer is, whether it has spread and general health.

If a cure is not realistic, in some cases treatment aims to control the cancer, limiting the growth or spread so it progresses less rapidly. This may limit the amount of symptoms for some time.

If the cancer is confined to the kidney without spreading, and the patient is in otherwise good general health, the outlook is good, with around 95 per cent of patients surviving five years after diagnosis (if the tumour is less than 4 cm). Surgical removal of an affected kidney in this situation gives a good chance of cure.

However, many people with kidney cancer are diagnosed when the cancer has already spread, so a cure is less likely. However, treatment can often slow down the progression of the cancer.

Follow-up care:-

Follow-up care after treatment for kidney cancer is important. Even when the cancer seems to have been completely removed or destroyed, the disease sometimes returns because cancer cells can remain in the body after treatment. The doctor monitors the recovery of the person treated for kidney cancer and checks for recurrence of cancer. Checkups help ensure that any changes in health are noted. The patient may have lab tests, chest x-rays, CT scans, or other tests.

Support for people with kidney cancer

Living with a serious disease such as kidney cancer is not easy. People with kidney cancer may worry about caring for their families, keeping their jobs, or continuing daily activities. Concerns about treatments and managing side effects, hospital stays, and medical bills are also common. Doctors, nurses, and other members of the health care team can answer questions about treatment, working, or other activities. Meeting with a social worker, counselor, or member of the clergy can be helpful to those who want to talk about their feelings or discuss their concerns. Often, a social worker can suggest resources for financial aid, transportation, home care, or emotional support.

Support groups also can help. In these groups, patients or their family members meet with other patients or their families to share what they have learned about coping with the disease and the effects of treatment. Groups may offer support in person, over the telephone, or on the Internet. Patients may want to talk with a member of their health care team about finding a support group.

The Cancer Information Service at 1-800-4-CANCER begin_of_the_skype_highlighting 1-800-4-CANCER end_of_the_skype_highlighting can provide information to help patients and their families locate programs, services, and publications.

The promise of cancer research:

Doctors all over the country are conducting many types of clinical trials. These are research studies in which people volunteer to take part. In clinical trials, doctors are testing new ways to treat kidney cancer. Research has already led to advances, and researchers continue to search for more effective approaches.

Patients who join these studies have the first chance to benefit from treatments that have shown promise in earlier research. They also make an important contribution to medical science by helping doctors learn more about the disease. Although clinical trials may pose some risks, researchers do all they can to protect their patients.

Researchers are studying surgery, biological therapy, chemotherapy, and combinations of these types of treatment. They also are combining chemotherapy with new treatments, like stem cell transplantation. A stem cell transplant allows a patient to be treated with high doses of drugs. The high doses destroy both cancer cells and normal blood cells in the bone marrow. Later, the patient receives healthy stem cells from a donor. New blood cells develop from the transplanted stem cells.

Other approaches also are under study. For example, researchers are studying cancer vaccines that help the immune system to find and attack kidney cancer cells.

Patients who are interested in being part of a clinical trial should talk with their doctor.

Disclaimer: This information is not meant to be a substitute for professional medical advise or help. It is always best to consult with a Physician about serious health concerns. This information is in no way intended to diagnose or prescribe remedies.This is purely for educational purpose

Resources:
http://www.bbc.co.uk/health/physical_health/conditions/in_depth/cancer/typescancer_kidney.shtml
http://en.wikipedia.org/wiki/Kidney_cancer
http://www.medicinenet.com/kidney_cancer/page7.htm

Kidney Cancer – Causes, Symptoms Diagnosis And Treatment

http://www-cancer.us/320/kidney-cancer-treatment/

Enhanced by Zemanta
Categories
Herbs & Plants

Blazing Star

[amazon_link asins=’0062410032,B004YNGVXY,1945769165,B00HMEA9GW,B00AZLRJ62,0606381643,B0150YED9Y,B00NLO4Z94,0615950981′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’41a2aa75-5bbf-11e7-8d71-c3660470e523′]

Botanical Name : Mentzelia albicaulis
Family: Loasaceae
Genus: Mentzelia
Species: M.
Kingdom: Plantae
Order: Cornales

Common Names :Blazing Star,Whitestem blazing star, Small flowered blazing star, White stemmed stickleaf

Habitat : Blazing Star is native to much of western North America, where it grows in mountain, desert, and plateau habitat.

Description:
Blazing Star is an annual herb producing a stem up to 42 centimeters long, sometimes growing erect. The leaves are up to 11 centimeters long in the basal rosette, divided into even comblike lobes, and smaller farther up on the plant. The flower has five shiny yellow petals 2 to 7 millimeters long each. The fruit is a narrow, straight or curving utricle 1 to 3 centimeters long. It contains many angular seeds covered in tiny bumps.
CLICK & SEE THE PICTURES…..
You may click to see more pictures of Blazing Star  : http://calphotos.berkeley.edu/cgi/img_query?where-genre=Plant&where-taxon=Mentzelia+albicaulis

Medicinal Uses:
A poultice of the crushed, soaked seeds has been applied to burns and also to relieve the pain of toothache. Used as a poultice and hot herb bath for arthritis and sprained or inflamed joints. Also used as a diuretic.  Simple tea as needed or for bathing

Disclaimer:
The information presented herein is intended for educational purposes only. Individual results may vary, and before using any supplements, it is always advisable to consult with your own health care provider.

Resources:
http://en.wikipedia.org/wiki/Mentzelia_albicaulis
http://www.pnwflowers.com/flower/mentzelia-albicaulis
http://plants.usda.gov/java/profile?symbol=MEAL6&photoID=meal6_012_ahp.jpg
http://www.herbnet.com/Herb%20Uses_AB.htm

Enhanced by Zemanta
Categories
Herbs & Plants

Blanket Flower

[amazon_link asins=’B019ET3L1W,B0055QAXG0,B003TCQDOI,B01DZ457VO,B006F6OFI6,B071V8141D,B009DSWMXS,B0062CVFUO,B01A7FUKJ8′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’ec6d5a9d-5bbf-11e7-9c22-2b97642d1575′]

Botanical Name : Gaillardia pinnatifida
Family: Asteraceae – Aster family
Genus: Gaillardia Foug. – blanketflower
Species: Gaillardia pinnatifida Torr. – red dome blanketflower
Kingdom :Plantae – Plants
Subkingdom: Tracheobionta – Vascular plants
Superdivision: Spermatophyta – Seed plants
Division: Magnoliophyta – Flowering plants
Class: Magnoliopsida – Dicotyledons
Subclass : Asteridae
Order: Asterales

Common Names:Red Dome Blanketflower, Slender Gaillardia,  Blanket Flower

Habitat :Native to USA. Upland, Mountain. This wildflower grows in dry, sunny, grassy areas.

Description:
Blanket Flower is a Perennial Subshrub, Herb/Forb , growing to  16 inches (41 cm) tall or more. Flower blooming period is Spring (late), Summer.
Flower Color is Yellow rays and reddish disks

CLICK  &  SEE  THE  PICTURES

The flower heads are 1 3/4 inches (4.4 cm) wide and have a fuzzy, domed, red disk ringed by yellow, 3-lobed rays. The seed heads are fuzzy, tan-colored, and ball-shaped. The leaves are linear, grayish green, covered in fine, whitish hairs, and variably pinnately-lobed with at least a few lobed leaves per plant.

Medicinal Uses:
The plant is used as a diuretic, taken to give relief from painful urination.  An infusion of the leaves is taken internally, and a poultice applied externally, in the treatment of gout.  For sinus or indigestion headaches, the plant is mashed and steeped in water or vinegar, and the resulting solution is applied to the head. One strong cup a day of the tea, taken for 7 days, is said to help infertility in women.  The hot tea, taken for several days is used for bladder pain and infections in the cold winter months.  A simple tea is brewed from the flowers for a blood tonic; it also is taken for anemia.  The powdered flowers can be inhaled for headaches, but some people are allergic to them

Special Characteristics: Butterfly Plant – The flowers attract butterflies

Disclaimer:
The information presented herein is intended for educational purposes only. Individual results may vary, and before using any supplements, it is always advisable to consult with your own health care provider.

Resources:
http://plants.usda.gov/java/profile?symbol=GAPI

Gaillardia pinnatifida – Red Dome Blanketflower


http://www.herbnet.com/Herb%20Uses_AB.htm

Enhanced by Zemanta
Categories
Ailmemts & Remedies Pediatric

Kawasaki disease

Alternative Names: Kawasaki syndrome, lymph node syndrome and mucocutaneous lymph node syndrome

Definition:
Kawasaki disease (KD) is an autoimmune disease that manifests as a systemic necrotizing medium-sized vessel vasculitis and is largely seen in children under five years of age. It affects many organ systems, mainly those including the blood vessels, skin, mucous membranes and lymph nodes; however, its most serious effect is on the heart where it can cause severe coronary artery aneurysms in untreated children. Without treatment, mortality may approach 1%, usually within six weeks of onset. With treatment, the mortality rate is less than 0.01% in the U.S. There is often a pre-existing viral infection that may play a role in its pathogenesis. The conjunctivae and oral mucosa, along with the epidermis (skin), become erythematous (red and inflamed). Edema is often seen in the hands and feet and one or both of the cervical lymph nodes are often enlarged. Also, a remittant fever, often 40? (104°F) or higher, is characteristic of the acute phase of the disease. In untreated children, the febrile period lasts on average approximately 10 days, but may range from five to 25 days. The disorder was first described in 1967 by Dr. Tomisaku Kawasaki in Japan.

CLICK & SEE

Kawasaki disease affects boys more than girls with people of Asian ethnicity, particularly Japanese and Korean most susceptible as well as people of Afro-Caribbean ethnicity. The disease was rare in Caucasians until the last few decades and incidence rate fluctuates from country to country.

By far the highest incidence of Kawasaki disease occurs in Japan (175 per 100,000).

However its incidence in the United States is increasing. Kawasaki disease is predominantly a disease of young children, with 80% of patients younger than five years of age. Approximately 2,000-4,000 cases are identified in the United States each year.

In the United Kingdom, estimates of incidence rate vary because of the rarity of Kawasaki disease. However Kawasaki disease is believed to affect fewer than 1 in every 25,000 people.  Incidence of the disease doubled from 1991 to 2000 however, with 4 cases in per 100,000 children in 1991 compared with a rise of 8 cases per 100,000 in 2000.

Symptoms:
Kawasaki disease often begins with a high and persistent fever that is not very responsive to normal treatment with paracetamol (acetaminophen) or ibuprofen.The fever may persist steadily for up to two weeks and is normally accompanied by irritability. Affected children develop red eyes because of non-suppurative conjunctivitis, iritis and bilateral anterior uveitis  Inflammation of the mucous membranes in the mouth, along with erythema (redness), edema (swelling) with fissures (cracks in the lip surface), desquamation (peeling) and exsudation of the lips are also evident. The oropharynx mucosa has enanthema and the tongue maintains an unusual red appearance termed “strawberry tongue” (marked erythema with prominent gustative papillae). Keratic precipitates (detectable by a slit lamp but usually too small to be seen by the unaided eye), and swollen lymph nodes may also be present and can be the first manifestation of the disease. Rashes occur early in the disease, and the cutaneous rash observed in patients with KD is non-specific, polymorphic, non-itchy and normally observed up to the fifth day of fever. Cutaneous exanthema may comprise macular-papular erythematous and fissure lesions, the most common type, in addition to urticariform type rash, purpuric, multiform-like erythema. and peeling of the skin in the genital area, hands, and feet (especially around the nails and on the palms and soles) may occur in later phases. Some of these symptoms may come and go during the course of the illness. It is a syndrome affecting multiple organ systems, and in the acute stage of KD, systemic inflammatory changes are evident in many organs. Myocarditis, pericarditis, valvulitis, aseptic meningitis, pneumonitis, lymphadenitis, and hepatitis may be present and are manifested by the presence of inflammatory cells in the affected tissues. If left untreated, some symptoms will eventually relent, but coronary artery aneurysms will not improve, resulting in a significant risk of death or disability due to myocardial infarction (heart attack). If treated in a timely fashion, this risk can be mostly avoided and the course of illness cut short

*High-grade fever (greater than 39 °C or 102 °F; often as high as 40 °C or 104 °F),  The duration of fever is on average one to two weeks; in the absence of treatment, it may extend for three to four weeks. However, when appropriate therapy is started the fever is gone after two days.

*Red eyes (conjunctivitis) bilateral without pus or drainage, also known as “conjunctival injection”.

*Anterior uveitis.

*Bright red, chapped, or cracked lips.

*Red mucous membranes in the mouth.

*Strawberry tongue, white coating on the tongue or prominent red bumps (papillae) on the back of the tongue.

*Red palms of the hands and the soles of the feet.

*Peeling (desquamation) palms and soles (later in the illness); peeling may begin around the nails.

*Rash which may take many forms, non-specific, polymorphic, non-itchy, but not vesicle-bullous lesions, and appears on the trunk.

*Swollen lymph nodes (frequently only one lymph node is swollen, and is usually on one side), particularly in the neck area.

*Joint pain (arthralgia) and swelling, frequently symmetrical, Also arthritis can occur.

*Irritability.

*Tachycardia (rapid heart beat).

*Beau’s lines (transverse grooves on nails).

*May find breathing difficult

Causes:
Like all autoimmune diseases, the cause of Kawasaki disease is presumably the interaction of genetic and environmental factors, possibly including an infection. The specific cause is unknown, but current theories center primarily on immunological causes for the disease. Evidence increasingly points to an infectious etiology, but debate continues on whether the cause is a conventional antigenic substance or a superantigen. Children’s Hospital Boston reported that “[s]ome studies have found associations between the occurrence of Kawasaki disease and recent exposure to carpet cleaning or residence near a body of stagnant water; however, cause and effect have not been established.”

An association has been identified with a SNP in the ITPKC gene, which codes an enzyme that negatively regulates T-cell activation. An additional factor that suggests genetic susceptibility is the fact that regardless of where they are living, Japanese children are more likely than other children to contract the disease. The HLA-B51 serotype has been found to be associated with endemic instances of the disease

Risk Factors:
Three things are known to increase your child’s risk of developing Kawasaki disease, including:

*Age. Children under 5 years old are most at risk of Kawasaki disease.

*Sex. Boys are slightly more likely than girls are to develop Kawasaki disease.

*Ethnicity. Children of Asian descent, such as Japanese or Korean, have higher rates of Kawasaki disease.

Diagnosis:
Kawasaki disease can only be diagnosed clinically (i.e. by medical signs and symptoms). There exists no specific laboratory test for this condition. It is difficult to establish the diagnosis, especially early in the course of the illness, and frequently children are not diagnosed until they have seen several health care providers. Many other serious illnesses can cause similar symptoms, and must be considered in the differential diagnosis, including scarlet fever, toxic shock syndrome, juvenile idiopathic arthritis, and childhood mercury poisoning (infantile acrodynia).

Classically, five days of fever  plus four of five diagnostic criteria must be met in order to establish the diagnosis. The criteria are: (1) erythema of the lips or oral cavity or cracking of the lips; (2) rash on the trunk; (3) swelling or erythema of the hands or feet; (4) red eyes (conjunctival injection) (5) swollen lymph node in the neck of at least 15 millimeters.

Many children, especially infants, eventually diagnosed with Kawasaki disease do not exhibit all of the above criteria. In fact, many experts now recommend treating for Kawasaki disease even if only three days of fever have passed and at least three diagnostic criteria are present, especially if other tests reveal abnormalities consistent with Kawasaki disease. In addition, the diagnosis can be made purely by the detection of coronary artery aneurysms in the proper clinical setting.

Investigations:
A physical examination will demonstrate many of the features listed above.

Blood tests:
*Complete blood count (CBC) may reveal normocytic anemia and eventually thrombocytosis

*Erythrocyte sedimentation rate (ESR) will be elevated

*C-reactive protein (CRP) will be elevated

*Liver function tests may show evidence of hepatic inflammation and low serum albumin

Other optional tests
*Electrocardiogram may show evidence of ventricular dysfunction or, occasionally, arrhythmia due to myocarditis

*Echocardiogram may show subtle coronary artery changes or, later, true aneurysms.

*Ultrasound or computerized tomography may show hydrops (enlargement) of the gallbladder

*Urinalysis may show white blood cells and protein in the urine (pyuria and proteinuria) without evidence of bacterial growth

*Lumbar puncture may show evidence of aseptic meningitis

*Angiography was historically used to detect coronary artery aneurysms and remains the gold standard for their detection, but is rarely used today unless coronary artery aneurysms have already been detected by echocardiography.

Complications :
•Inflammation of the blood vessels (vasculitis)
•Inflammation of the heart muscle (myocarditis)
•Aneurysms in arteries that increase the risk of blood clots and heart attacks

Treatment :
Children with Kawasaki disease should be hospitalized and cared for by a physician who has experience with this disease. When in an academic medical center, care is often shared between pediatric cardiology and pediatric infectious disease specialists (although no specific infectious agent has been identified as yet). It is imperative that treatment be started as soon as the diagnosis is made to prevent damage to the coronary arteries.

Intravenous immunoglobulin (IVIG) is the standard treatment for Kawasaki disease[38] and is administered in high doses with marked improvement usually noted within 24 hours. If the fever does not respond, an additional dose may have to be considered. In rare cases, a third dose may be given to the child. IVIG by itself is most useful within the first seven days of onset of fever, in terms of preventing coronary artery aneurysm.

Salicylate therapy, particularly aspirin, remains an important part of the treatment (though questioned by some) but salicylates alone are not as effective as IVIG. Aspirin therapy is started at high doses until the fever subsides, and then is continued at a low dose when the patient returns home, usually for two months to prevent blood clots from forming. Except for Kawasaki disease and a few other indications, aspirin is otherwise normally not recommended for children due to its association with Reye’s syndrome. Because children with Kawasaki disease will be taking aspirin for up to several months, vaccination against varicella and influenza is required, as these infections are most likely to cause Reye’s syndrome.

Corticosteroids have also been used, especially when other treatments fail or symptoms recur, but in a randomized controlled trial, the addition of corticosteroid to immune globulin and aspirin did not improve outcome. Additionally, corticosteroid use in the setting of Kawasaki disease is associated with increased risk of coronary artery aneurysm, and so its use is generally contraindicated in this setting. In cases of kawasaki disease refractory to IVIG, cyclophosphamide and plasma exchange have been investigated as possible treatments, with variable outcomes.

There are also treatments for iritis and other eye symptoms. Another treatment may include the use of Infliximab (Remicade). Infliximab works by binding tumour necrosis factor alpha

Prognosis:
With early treatment, rapid recovery from the acute symptoms can be expected and the risk of coronary artery aneurysms greatly reduced. Untreated, the acute symptoms of Kawasaki disease are self-limited (i.e. the patient will recover eventually), but the risk of coronary artery involvement is much greater. Overall, about 2% of patients die from complications of coronary vasculitis. Patients who have had Kawasaki disease should have an echocardiogram initially every few weeks, and then every one or two years to screen for progression of cardiac involvement.

It is also not uncommon that a relapse of symptoms may occur soon after initial treatment with IVIG. This usually requires re-hospitalization and re-treatment. Treatment with IVIG can cause allergic and non-allergic acute reactions, aseptic meningitis, fluid overload and, rarely, other serious reactions. Overall, life-threatening complications resulting from therapy for Kawasaki disease are exceedingly rare, especially compared with the risk of non-treatment. There is also evidence that Kawasaki disease produces altered lipid metabolism that persists beyond clinical resolution of the disease.

Disclaimer: This information is not meant to be a substitute for professional medical advise or help. It is always best to consult with a Physician about serious health concerns. This information is in no way intended to diagnose or prescribe remedies.This is purely for educational purpose

Resources:
http://en.wikipedia.org/wiki/Kawasaki_disease
http://www.bbc.co.uk/health/physical_health/conditions/kawasaki2.shtml
http://www.vaheart.com/kawasaki-disease/
http://www.mayoclinic.com/health/kawasaki-disease/DS00576/DSECTION=risk-factors

Enhanced by Zemanta
Categories
News on Health & Science

Drinking Coffee may Reduce The Risk of Prostate Cancer

[amazon_link asins=’B010ULFOWC,B006CQ1ZHI,B00FL6PCF6,B001G2F5R4,B00BH1005Q,B000FUYCJ0,B00I08JAYG,B008P731LK,B014KG4YZ6′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’87b824e6-5bc0-11e7-86ff-13c98e6bc329′]

While many scientists have wondered about a possible link between coffee and a lower the risk of prostate cancer, most studies to date have been relatively small and shown mixed results. But a new study followed almost 50,000 male health professionals for more than two decades.

According to the research, for the men who drank the most coffee, the risk of getting the most deadly form of prostate cancer was about 60 percent lower.

NPR reports:
“The new study shows that getting a 60 percent reduction in risk of aggressive prostate cancer requires a lot of coffee — at least six cups a day. However, men who drank three cups a day had a 30 percent lower chance of getting a lethal prostate cancer, and that’s not bad.”

Resources:
*NPR May 18, 2011
*Journal of the National Cancer Institute May 17, 2011

Posted By Dr. Mercola | June 02 2011

Enhanced by Zemanta
css.php